CytomX Therapeutics Inc (CTMX) : Vhcp Management Ii reduced its stake in CytomX Therapeutics Inc by 4.18% during the most recent quarter end. The investment management company now holds a total of 577,831 shares of CytomX Therapeutics Inc which is valued at $5.8 Million after selling 25,200 shares in CytomX Therapeutics Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.CytomX Therapeutics Inc makes up approximately 3.71% of Vhcp Management Ii’s portfolio.
Other Hedge Funds, Including , Manufacturers Life Insurance Company The added CTMX to its portfolio by purchasing 5,800 company shares during the most recent quarter which is valued at $58,000. New York State Common Retirement Fund added CTMX to its portfolio by purchasing 7,300 company shares during the most recent quarter which is valued at $88,403.Schwab Charles Investment Management Inc boosted its stake in CTMX in the latest quarter, The investment management firm added 357 additional shares and now holds a total of 22,928 shares of CytomX Therapeutics Inc which is valued at $277,658.
CytomX Therapeutics Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company’s pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company’s additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.